Sign In
Buy ALT
$2.84
-0.140 (-4.70%)
At Close: Jul 31, 2026
Altimmune's drug for a type of liver disease shows benefits in mid-stage study
06:42am, Friday, 19'th Dec 2025
Altimmune said on Friday its experimental drug improved signs of liver scarring and liver health after 48 weeks of treatment in a mid-stage study of patients with a serious fatty liver disease known a
Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial
06:30am, Friday, 19'th Dec 2025
Improvements observed in key non-invasive markers of fibrosis across treatment arms versus placebo, with continued reductions from 24-week timepoint
ALT5 Sigma Corporation Issues Stockholder Letter From CEO Tony Isaac
08:00am, Thursday, 18'th Dec 2025
LAS VEGAS--(BUSINESS WIRE)--ALT5 Sigma Corporation (the “Company” or “ALT5”) (NASDAQ: ALTS)(FRA: 5AR1), a fintech company operating institutional-grade global payments, trading, and settlement
SAN DIEGO , Dec. 11, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving ALT5 Sigma Corporation (NASDAQ: ALTS) focus
Does Altimmune (ALT) Have the Potential to Rally 229.28% as Wall Street Analysts Expect?
10:56am, Thursday, 11'th Dec 2025
The consensus price target hints at a 229.3% upside potential for Altimmune (ALT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimat
LAS VEGAS--(BUSINESS WIRE)--ALT5 Sigma Corporation (the “Company,” “our” or “ALT5”) (NASDAQ: ALTS) (FRA:5AR1), a fintech company with established global payments, trading, and settlement i
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In ALT5 (ALTS) To Contact Him Directly To Discuss Their Options If you purchased or acquire
ALT5 Sigma Corporation Provides Corporate Update
07:30am, Tuesday, 09'th Dec 2025
LAS VEGAS--(BUSINESS WIRE)--ALT5 Sigma Corporation (the “Company” or “ALT5”) (NASDAQ: ALTS) (FRA:5AR1), a fintech company advancing a strategic $WLFI digital asset treasury initiative, today i
ALT5 Sigma Receives Expected Nasdaq Notification Regarding Late Filing of Form 10-Q
04:01pm, Tuesday, 02'nd Dec 2025
LAS VEGAS--(BUSINESS WIRE)--ALT 5 Sigma Corporation (the “Company” or “ALT5”) (NASDAQ: ALTS)(FRA: 5AR1) today announced that it received a notification letter (the “Letter”) from the Nasda
Altimmune Announces CEO Transition and Succession Plan
07:30am, Monday, 01'st Dec 2025
Altimmune announces CEO transition and succession plan under which Jerry Durso will assume the role of President and Chief Executive Officer on January 1.
Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference
07:30am, Wednesday, 26'th Nov 2025
GAITHERSBURG, Md., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometa
Wall Street Analysts Predict a 250.59% Upside in Altimmune (ALT): Here's What You Should Know
10:56am, Tuesday, 25'th Nov 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 250.6% in Altimmune (ALT). While the effectiveness of this highly sought-after metric is questionable, the posi
Investors Purchase High Volume of Altimmune Call Options (NASDAQ:ALT)
01:20am, Tuesday, 25'th Nov 2025
Altimmune, Inc. (NASDAQ: ALT - Get Free Report) saw unusually large options trading on Monday. Investors bought 11,978 call options on the stock. This represents an increase of 103% compared to the av
Altimmune, Inc. (ALT) Presents at Jefferies London Healthcare Conference 2025 Transcript
03:03pm, Thursday, 20'th Nov 2025
Altimmune, Inc. ( ALT ) Jefferies London Healthcare Conference 2025 November 20, 2025 3:00 AM EST Company Participants Vipin Garg - President, CEO & Director Christophe Arbet-Engels - Chief Medical Of
Altimmune: Probing Pemvi's MASH Data
03:23am, Friday, 14'th Nov 2025
Altimmune remains a speculative buy as pemvidutide shows strong Phase IIb MASH results, confirmed by a recent Lancet publication. ALT's pemvidutide demonstrates significant MASH resolution, fibrosis i
